Flu: Transferring excess QIV vaccines between providers

Flu: Transferring excess QIV vaccines between providers

November 8, 2019

NHS England and NHS Improvement (NHSE&I) have issued a letter advising that the Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed that that due to the current supply issues with quadrivalent influenza vaccines (QIV), it would not prevent the transfer of these vaccines between providers. This could apply, for example, from a community pharmacy to a GP practice or vice versa. This applies to both the egg-grown quadrivalent influenza vaccine (QIVe) and the newly licenced cell-based quadrivalent influenza vaccine (QIVc).

The MHRA has advised that for this transfer to be allowed the following conditions must be met:

  • the practice, pharmacy or NHS Trust that is holding the excess QIV stock has assurance that the vaccine has been stored in the correct temperature-controlled conditions;
  • confirmed record keeping of temperature monitoring is available;
  • the practice, pharmacy or NHS Trust that requests QIV is able to verify the assurances given; and
  • the vaccine can be transported appropriately under the right cold chain conditions.

The letter also refers to live attenuated influenza vaccine (LAIV), however, this vaccine is only licensed for the children’s flu vaccination programme and community pharmacists cannot vaccinate children as part of the national NHS Flu Vaccination Service.

The letter also contains an embedded PDF of an NHSE&I letter issued on 17th July 2019, but this functionality does not work in the document; a copy of that letter can be separately downloaded via the following link: Public Health England and NHSE&I letter regarding flu vaccine supplies (17th July 2019) 


Posted in:

More Latest News >